Validation of a 3D Instrumented Serious Game to Evaluate Upper Limb Impairments in Children With Neuromotor Disorders
Launched by UNIVERSITY HOSPITAL, GENEVA · Jan 8, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new 3D serious game designed to help assess how well children with neuromotor disorders, like cerebral palsy or brain injuries, can move their arms. The researchers want to find out if this game can accurately measure upper limb movements and if it is more engaging and enjoyable for children compared to traditional assessment methods. They will compare the results of children with neuromotor disorders to those of typically developing children to see how well the game works.
To participate, children need to be between 5 and 13 years old and have a non-progressive neurological condition that affects their movement but allows them to grasp objects. Children who are typically developing can also join if they meet the age requirement. Participants will come to the hospital for one or two visits, where they will play the new game and undergo some assessments. This trial is not yet recruiting participants, but it aims to offer valuable insights into how we can better understand and treat upper limb impairments in children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children with NMD
- • Informed Consent signed by the subject
- • Aged from 5 to 13 years,
- • Non-progressive neurological lesions (cerebral palsy, stroke, traumatic brain injury, etc.),
- • With sufficient grasp ability to perform the 3D protocol tasks (MACS level I to III),
- • TD children
- • Informed Consent signed by the subject
- • Aged from 5 to 13 years,
- Exclusion Criteria:
- • Children with neuromotor disorders
- • inability to follow the procedures of the investigation because of severe cognitive or visual disturbances,
- • upper limb (UL) disorders that may affect movement (fractures less than 6 months prior to participation, pain (visual analogic score (VAS) score \> 0), etc.).
- • previous UL surgery, and botulinum toxin injections less than three months prior to participation,
- • TD children
- • Inability to follow the procedures of the investigation because of severe visual disturbances,
- • UL disorders that may affect movement (fractures less than 6 months prior to participation, pain (VAS score \> 0), etc.).
About University Hospital, Geneva
The University Hospital of Geneva is a leading academic medical center committed to advancing healthcare through innovative research and clinical excellence. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge medical research with high-quality patient care, fostering a collaborative environment that encourages the translation of scientific discoveries into practical treatments. As a prominent sponsor of clinical trials, the University Hospital of Geneva is dedicated to exploring new therapies and improving patient outcomes, while adhering to the highest ethical standards and regulatory compliance. Its robust infrastructure and expert clinical teams ensure the efficient execution of trials across various medical specialties, contributing significantly to the advancement of global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported